Phase 2 N=48 Single-blind Supportive Care

Adipose Tissue Extract and Platelet-rich Plasma Use for Wound Healing

Wound Healing Disturbance of

Bottom Line

View on ClinicalTrials.gov: NCT02799290 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2021

Primary outcome: Primary: Wound Re-epithelization — 12.34; 10.27; 11.33 days

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: ADIPOSE TISSUE EXTRACT (Biological); PLATELET-RICH PLASMA GEL (Biological)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Tampere University
Primary completion: May 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Wound Re-epithelization	12.34; 10.27; 11.33	—
SECONDARY Scar Properties	8.13; 4.86; 6.46; 6.85; 5.66; 2.4	—
SECONDARY Oxygenated Hemoglobin	0.36; 0.20; 0.24; 0.28; 0.18; 0.19	—
SECONDARY Melanin Concentration in Wound	0.02; 0.03; 0.03; 0.03; 0.01; 0.02	—

Summary

Adipose Tissue Extract (ATE) has been found to be an autologous source of growth factors with proven in vitro angiogenic and adipogenic properties.It is obtained by a simple lipoaspirate procedure. We sought to compare the effect of ATE with another known source, platelet-rich plasma to compare the wound healing characteristics on skin graft donor sites.

Eligibility Criteria

Inclusion Criteria

donor site indication

Exclusion Criteria

immunosupressive states
terminal renal insufficiency
pregnancy
coagulation dyscrasias
active infection in donor site

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02799290). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.